Viral gene transfer
Gene transfer techniques are an important tool in studies of gene function as well as in the clinical evaluation of new treatments. In research the most important impact of efficient transient and stable gene transfer methods is the generation of new cell lines or animal models for the basic research of protein functions. Many of these methods are based on utilization of viruses as means to target and deliver genes into appropriate cells. Alternatively, recent advances in the RNAi-methodology enable the same delivery method to be used to efficiently silence specific genes in cells.
Successful work with sophisticated viral methods requires special expertise and strict safety considerations both of which are found at all of the biocenters in Finland.
BCK National Virus Vector Core Facility
Production of adenoviral, lentiviral, AAV and baculoviral vectors for in vitro and in vivo work.
Training of researchers for in vitro and in vivo animal gene transfer methods.
Helsinki Institute of Life Science - HiLIFE
Biomedicum Functional Genomics Unit (FuGU): (lenti and retroviruses)
AAV Gene Transfer and Cell Therapy Core Facility: Recombinant adeno-associated virus (AAV) preps.
Cancer gene therapy group: oncolytic viruses
Biocenter Oulu Virus Vector Core Facility: Production of adeno and lentiviruses
Viral Vector Facility: recombinant viral (Lenti and Adeno) vectors
Faculty of Medicine and Life Sciences
BMT Tampere Virus Vector Facility: Small and medium scale virus production (retro and lentiviruses)
Also University of Jyväskylä Vector Core facility participates in the Biocenter Finland National Imaging Infrastructure Network activities: Live and still virus imaging (external member), Jyväskylä Environmental and Nanoscience Center, University of Jyväskylä, Maija Vihinen-Ranta
Seppo Ylä-Herttuala / tel. +358 40 355 2075 / seppo.ylaherttuala(at)uef.fi
Biocenter Kuopio, University of Eastern Finland
The A. I. Virtanen Institute, Molecular Medicine Research Group
National Virus Vector Laboratory
Viral Gene Transfer and Cell Therapy Technology Platform (VGTCT) partners:
Seppo Ylä-Herttuala (Chair of the consortium), BCK, National Virus Core Facility, A. I. Virtanen Institute; Kari Alitalo, BCH, AAV Gene Transfer and Cell Therapy Core Facility; Akseli Hemminki, BCH, Oncolytic vector core facility; Juha Klefström, BCH, Functional Genomics Unit (FuGu); Aki Manninen, BCO, Virus Vector Core Facility; Eric Dufour, BMT Virus Vector Facility; Eleanor Coffey, BioCity, Viral Vector Facility. External member: Maija Vihinen-Ranta, University of Jyväskylä